company background image
PRM

Proteome SciencesAIM:PRM Stock Report

Market Cap

UK£16.2m

7D

-6.1%

1Y

48.6%

Updated

01 Dec, 2021

Data

Company Financials
PRM fundamental analysis
Snowflake Score
Valuation2/6
Future Growth0/6
Past Performance5/6
Financial Health0/6
Dividends0/6

PRM Stock Overview

Proteome Sciences plc provides contract research services for the identification, validation, and application of protein biomarkers in the United States, the United Kingdom, and European Union.

Price History & Performance

Summary of all time highs, changes and price drops for Proteome Sciences
Historical stock prices
Current Share PriceUK£0.053
52 Week HighUK£0.10
52 Week LowUK£0.031
Beta0.0040
1 Month Change2.89%
3 Month Change-6.14%
1 Year Change48.61%
3 Year Change91.07%
5 Year Change-5.06%
Change since IPO-96.66%

Recent News & Updates

May 31
Does Proteome Sciences (LON:PRM) Deserve A Spot On Your Watchlist?

Does Proteome Sciences (LON:PRM) Deserve A Spot On Your Watchlist?

Like a puppy chasing its tail, some new investors often chase 'the next big thing', even if that means buying 'story...

Apr 04
Some Confidence Is Lacking In Proteome Sciences plc's (LON:PRM) P/E

Some Confidence Is Lacking In Proteome Sciences plc's (LON:PRM) P/E

Proteome Sciences plc's ( LON:PRM ) price-to-earnings (or "P/E") ratio of 40x might make it look like a strong sell...

Shareholder Returns

PRMGB Life SciencesGB Market
7D-6.1%1.3%-2.6%
1Y48.6%10.0%10.9%

Return vs Industry: PRM exceeded the UK Life Sciences industry which returned 12.6% over the past year.

Return vs Market: PRM exceeded the UK Market which returned 13.8% over the past year.

Price Volatility

Is PRM's price volatile compared to industry and market?
PRM volatility
PRM Average Weekly Movement5.6%
Life Sciences Industry Average Movement7.0%
Market Average Movement4.9%
10% most volatile stocks in GB Market9.8%
10% least volatile stocks in GB Market2.5%

Stable Share Price: PRM is not significantly more volatile than the rest of UK stocks over the past 3 months, typically moving +/- 6% a week.

Volatility Over Time: PRM's weekly volatility has decreased from 11% to 6% over the past year.

About the Company

FoundedEmployeesCEOWebsite
199324Mariola Söhngenhttps://www.proteomics.com

Proteome Sciences plc provides contract research services for the identification, validation, and application of protein biomarkers in the United States, the United Kingdom, and European Union. The company develops the technology for isobaric tandem mass tag (TMT) and TMTpro; and manufactures small and protein-reactive chemical reagents. It offers SysQuant provides comprehensive analysis of protein activity across regulatory and signaling pathways; TMT MS2 for analyzing cells and tissues when no phosphopeptide enrichment is required; and TMT MS3, a method for biomarker discovery in plasma and other complex samples where quantitative accuracy is the most important factor.

Proteome Sciences Fundamentals Summary

How do Proteome Sciences's earnings and revenue compare to its market cap?
PRM fundamental statistics
Market CapUK£16.24m
Earnings (TTM)UK£384.00k
Revenue (TTM)UK£4.82m

41.2x

P/E Ratio

3.3x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
PRM income statement (TTM)
RevenueUK£4.82m
Cost of RevenueUK£2.15m
Gross ProfitUK£2.68m
ExpensesUK£2.29m
EarningsUK£384.00k

Last Reported Earnings

Jun 30, 2021

Next Earnings Date

n/a

Earnings per share (EPS)0.0013
Gross Margin55.50%
Net Profit Margin7.96%
Debt/Equity Ratio-289.2%

How did PRM perform over the long term?

See historical performance and comparison

Valuation

Is Proteome Sciences undervalued compared to its fair value and its price relative to the market?

8.0%

Undervalued compared to fair value


Share Price vs. Fair Value

Below Fair Value: PRM (£0.06) is trading below our estimate of fair value (£0.06)

Significantly Below Fair Value: PRM is trading below fair value, but not by a significant amount.


Price To Earnings Ratio

PE vs Industry: PRM is good value based on its PE Ratio (42.3x) compared to the European Life Sciences industry average (46.3x).

PE vs Market: PRM is poor value based on its PE Ratio (42.3x) compared to the UK market (19x).


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate PRM's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: PRM has negative assets, so we can't compare its PB Ratio to the GB Life Sciences industry average.


Future Growth

How is Proteome Sciences forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

10.6%

Forecasted Pharmaceuticals & Biotech industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Proteome Sciences has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Past Performance

How has Proteome Sciences performed over the past 5 years?

56.6%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: PRM has high quality earnings.

Growing Profit Margin: PRM's current net profit margins (8%) are higher than last year (1.3%).


Past Earnings Growth Analysis

Earnings Trend: PRM has become profitable over the past 5 years, growing earnings by 56.6% per year.

Accelerating Growth: PRM's earnings growth over the past year (529.5%) exceeds its 5-year average (56.6% per year).

Earnings vs Industry: PRM earnings growth over the past year (529.5%) exceeded the Life Sciences industry 77.1%.


Return on Equity

High ROE: PRM's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.


Financial Health

How is Proteome Sciences's financial position?


Financial Position Analysis

Short Term Liabilities: PRM has negative shareholder equity, which is a more serious situation than short term assets not covering short term liabilities.

Long Term Liabilities: PRM has negative shareholder equity, which is a more serious situation than short term assets not covering long term liabilities.


Debt to Equity History and Analysis

Debt Level: PRM has negative shareholder equity, which is a more serious situation than a high debt level.

Reducing Debt: PRM's has negative shareholder equity, so we do not need to check if its debt has reduced over time.

Debt Coverage: PRM's debt is not well covered by operating cash flow (8.3%).

Interest Coverage: PRM's interest payments on its debt are not well covered by EBIT (2.1x coverage).


Balance Sheet


Dividend

What is Proteome Sciences's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate PRM's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate PRM's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if PRM's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if PRM's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of PRM's dividend in 3 years as they are not forecast to pay a notable one for the UK market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

4.4yrs

Average management tenure


CEO

Mariola Söhngen (60 yo)

1.17yrs

Tenure

UK£251,908

Compensation

Dr. Mariola Söhngen serves as Chief Executive Officer and Executive Director at Proteome Sciences plc since September 15, 2020. Dr. Söhngen served as a Member of the Executive Board of Mologen AG since Nov...


CEO Compensation Analysis

Compensation vs Market: Mariola's total compensation ($USD333.54K) is about average for companies of similar size in the UK market ($USD324.53K).

Compensation vs Earnings: Insufficient data to compare Mariola's compensation with company performance.


Leadership Team

Experienced Management: PRM's management team is considered experienced (4.4 years average tenure).


Board Members

Experienced Board: PRM's board of directors are considered experienced (7.1 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

Proteome Sciences plc's employee growth, exchange listings and data sources


Key Information

  • Name: Proteome Sciences plc
  • Ticker: PRM
  • Exchange: AIM
  • Founded: 1993
  • Industry: Life Sciences Tools and Services
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: UK£16.235m
  • Shares outstanding: 295.18m
  • Website: https://www.proteomics.com

Number of Employees


Location

  • Proteome Sciences plc
  • 5 Dashwood Lang Road
  • Bourne Business Park
  • Addlestone
  • Surrey
  • KT15 2HJ
  • United Kingdom

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/12/01 19:05
End of Day Share Price2021/12/01 00:00
Earnings2021/06/30
Annual Earnings2020/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.